20
May
2016
Genentech Enters the PD-L1 Arena, Theranos in Ashes & the ASCO PR Machine Revs Up
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
May
2016
I-O: Who’s Doing What? (Part 2)
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
May
2016
Immuno-Oncology: Who’s Doing What?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
May
2016
John Oliver’s Rant, the Sid Mukherjee Tempest & A Lung Cancer Mea Culpa
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
May
2016
Bull Market or Bubble? Watch My Chat with Biotech Leaders at Milken Global
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
May
2016
Prince Puts a Face on Opioids, IMS Buys Quintiles & Sarepta Running Wild
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
May
2016
How Much Scrutiny is Biopharma Facing? Not as Much as You Might Think
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Apr
2016
Congress Slaughters Hogs, Sarepta’s Bad Day & Soon-Shiong’s 9-Figure Payday
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Apr
2016
Theranos May Be The Trigger That Brings Order to the Diagnostic Wild West
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Apr
2016
Sarepta in the Lion’s Den, Theranos Hits Bottom, & Pharma’s Microbiome Foray
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Apr
2016
See the Photos from the TR Anniversary Party in Boston
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Apr
2016
Medivation Stiffs Sanofi, IMS on Drug Spending, & Billionaire Worship
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Apr
2016
12 VCs Who Matter, But You Never Read About
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Apr
2016
PfizerGan Unravels, Gilead Gets NASH Drug, & Verily Self-Dealing
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Apr
2016
Seattleites: Join Chad and Harlan Robins for an Interview at the TR Anniversary Apr. 25
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Apr
2016
How Can Migraine Drugmakers Avoid the PCSK9 Debacle?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Apr
2016
Medivation Under the Microscope, Obama’s Opioid Plan, & Burrill’s Ban
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
Mar
2016
Join TR and STAT For a Conversation About Health Science Journalism Apr. 14
The TR Anniversary Party is coming up fast on Apr. 14, and I’m excited. You can look forward to top-notch industry networking, but also a short and lively program on the future of quality biotech journalism. STAT executive editor Rick Berke, the guy spearheading an ambitious new venture in health science journalism, has agreed to join me for a fireside chat... Read More
28
Mar
2016
When Does it Make Sense to Acqui-Hire in Biotech?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Mar
2016
Merck Beats Gilead in Court, BMS Locks Up Padlock, & Allen’s $100M Biotech Bet
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.